Other therapies focus on the treatment of hyperphosphorylated tau protein aggregates, that are a histopathological hallmark of AD and other related tauopathies [24], or on more generic targets such as neuroinflammation and neuronal mitochondrial dysfunction [25]. The gene discussed is MAPT; the disease is Alzheimer disease.